Target Price | $18.36 |
Price | $3.75 |
Potential |
389.60%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Altimmune, Inc. 2026 .
The average Altimmune, Inc. target price is $18.36.
This is
389.60%
register free of charge
$29.40
684.00%
register free of charge
$1.01
73.07%
register free of charge
|
|
A rating was issued by 14 analysts: 11 Analysts recommend Altimmune, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Altimmune, Inc. stock has an average upside potential 2026 of
389.60%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 0.02 | 0.00 |
95.35% | 81.00% | |
EBITDA Margin | -514,650.00% | -2,885,686.67% |
2,565.30% | 460.71% | |
Net Margin | -475,300.00% | -2,531,708.54% |
2,210.67% | 432.65% |
10 Analysts have issued a sales forecast Altimmune, Inc. 2025 . The average Altimmune, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Altimmune, Inc. EBITDA forecast 2025. The average Altimmune, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Altimmune, Inc. Analysts have issued a net profit forecast 2025. The average Altimmune, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.34 | -1.13 |
19.28% | 15.67% | |
P/E | negative | |
EV/Sales | 42,822.44 |
11 Analysts have issued a Altimmune, Inc. forecast for earnings per share. The average Altimmune, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Altimmune, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
B. Riley Securities |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
UBS |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
Analyst Rating | Date |
---|---|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Aug 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 13 2025 |
Locked
UBS:
Locked
➜
Locked
|
Aug 13 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Apr 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.